We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+4.21%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$418M
AUM Growth
+$84.2M
Cap. Flow
+$97.8M
Cap. Flow %
23.4%
Top 10 Hldgs %
66.46%
Holding
52
New
11
Increased
13
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$85.1M
2
GERN icon
Geron
GERN
+$6.69M
3
CBAY
Cymabay Therapeutics
CBAY
+$5.28M
4
KROS icon
Keros Therapeutics
KROS
+$5.03M
5
NTLA icon
Intellia Therapeutics
NTLA
+$4.87M

Top Sells

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$5.52M
2
TELA icon
TELA Bio
TELA
+$5.04M
3
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$4.21M
4
PHAT icon
Phathom Pharmaceuticals
PHAT
+$3.54M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$2.95M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
26
Cytokinetics
CYTK
$10.8B
$4.24M 1.01%
130,000
-77,500
-37% -$2.87M
TRVI icon
27
Trevi Therapeutics
TRVI
$2.56B
$4.07M 0.97%
1,701,500
+865,700
+104% +$2.18M
GOSS icon
28
Gossamer Bio
GOSS
$83.2M
$4.04M 0.97%
+3,370,000
New +$4.2M
FDMT icon
29
4D Molecular Therapeutics
FDMT
$824M
$4.01M 0.96%
221,700
-92,300
-29% -$1.7M
NYXH
30
Nyxoah
NYXH
$160M
$3.56M 0.85%
445,000
+387,415
+673% +$3.16M
FOCL
31
EDAP TMS S.A.
FOCL
$199M
$3.5M 0.84%
380,000
-2,400
-0.6% -$24.6K
KPTI icon
32
Karyopharm Therapeutics
KPTI
$44M
$3.2M 0.76%
119,000
-68,387
-36% -$2.95M
IOVA icon
33
Iovance Biotherapeutics
IOVA
$3.74B
$2.96M 0.71%
421,000
– –
STXS icon
34
Stereotaxis
STXS
$147M
$2.95M 0.71%
3,074,995
+2,207,895
+255% +$4.09M
ATXS
35
DELISTED
Astria Therapeutics
ATXS
$2.54M 0.61%
305,000
+3,000
+1% +$34.6K
CDXS icon
36
Codexis
CDXS
$182M
$1.89M 0.45%
675,000
-75,000
-10% -$243K
FBIO icon
37
Fortress Biotech
FBIO
$93.4M
$1.82M 0.44%
220,667
-84,240
-28% -$833K
STRO icon
38
Sutro Biopharma
STRO
$353M
$1.43M 0.34%
+30,700
New +$1.53M
BDTX icon
39
Black Diamond Therapeutics
BDTX
$130M
$1.39M 0.33%
+275,000
New +$562K
TCON
40
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$1.39M 0.33%
238,225
– –
PRQR icon
41
ProQR Therapeutics
PRQR
$327M
$1.06M 0.25%
653,000
– –
JNCE
42
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$918K 0.22%
669,944
-2,210,056
-77% -$4.21M
VSTM icon
43
Verastem
VSTM
$668M
$759K 0.18%
+102,000
New +$708K
XOMA
44
DELISTED
Xoma
XOMA
$595K 0.14%
275,000
+32,000
+13% +$600K
IGMS
45
DELISTED
IGM Biosciences
IGMS
$586K 0.14%
+63,500
New +$711K
FULC icon
46
Fulcrum Therapeutics
FULC
$294M
$474K 0.11%
+143,600
New +$422K
KZR
47
DELISTED
Kezar Life Sciences
KZR
$242K 0.06%
9,880
-52,620
-84% -$1.37M
ARQT icon
48
Arcutis Biotherapeutics
ARQT
$3.13B
– –
-502,000
Closed -$5.52M
MLYS icon
49
Mineralys Therapeutics
MLYS
$2.3B
– –
-115,000
Closed -$1.8M
MODD icon
50
Modular Medical
MODD
$29.4M
– –
-6,117
Closed -$266K
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2023 Portfolio in Review

As of Q2 2023, Opaleye Management held 52 positions worth $418M, up 25% from $334M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Opaleye Management deployed $97.8M of net new capital in Q2 2023, opening 11 new positions and adding to 13 existing holdings. Its largest new stake was ACELYRIN: 4,158,638 shares worth $86.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was TELA Bio, an estimated $5.04M trimmed.

  • Opaleye Management's largest Q2 2023 buy was ACELYRIN: 4,158,638 shares worth $86.9M.
  • Opaleye Management added most to Keros Therapeutics in Q2 2023, an estimated $5.03M increase.
  • Opaleye Management's biggest Q2 2023 reduction was TELA Bio, cutting an estimated $5.04M.
  • Opaleye Management fully exited Arcutis Biotherapeutics in Q2 2023, selling an estimated $5.52M.
  • Opaleye Management's ten largest holdings make up 66% of its $418M portfolio in Q2 2023.
  • Opaleye Management opened 11 new positions and closed 5 in Q2 2023.
  • Opaleye Management's portfolio value rose 25% quarter-over-quarter to $418M.

Based on Opaleye Management's 13F filing for Q2 2023, filed 14 Aug 2023.